EGFR mutations (L858R point mutation and exon 19 deletion) in lung cancer have been well studied and testified to have good effects of EGFR tyrosine kinase inhibitor (TKI) such as gefitinib and erlotinib. The gene discussed is EGFR; the disease is lung cancer.